Karyopharm Seeks Accelerated FDA Approval for Myelofibrosis Treatment

Karyopharm Therapeutics has submitted a supplemental New Drug Application to the FDA, aiming to bring its drug XPOVIO in combination with ruxolitinib to patients suffering from myelofibrosis. The company has requested a Priority Review for the therapy, which could compress the regulatory evaluation period to six months.

Money Talk·August 31, 2026·reads: 1,331

The filing follows positive results from the Phase 3 SENTRY trial, which demonstrated that the combination therapy provides sustained spleen volume reduction and potential overall survival benefits. Karyopharm is pursuing the Accelerated Approval pathway, contingent on the FDA accepting spleen volume reduction as a surrogate endpoint for clinical success. Chief Medical Officer Reshma Rangwala noted that the trial data suggests the combination could fundamentally alter the treatment landscape for a disease that currently relies primarily on JAK inhibitors.

Karyopharm expects to receive formal notification regarding the filing status and potential review timeline in the fourth quarter of 2026. If granted, the company intends to use long-term survival data from the SENTRY study to confirm the clinical benefit and transition toward traditional approval. Myelofibrosis remains a significant challenge, affecting approximately 20,000 patients in the United States, and the company is positioning this combination as a vital option for those facing limited therapeutic alternatives.